Medium2 marksMultiple Choice
Financial ReportingSection BIFRS 10ConsolidationNCI

ACCA · Question 27 · Financial Reporting

Section B - Case 3: BioHealth Holdings

BioHealth Holdings acquired 75% of the equity share capital of MedTech Co on 1 January 20X8 for $8,500,000. At the acquisition date, the fair value of MedTech's net assets was $9,200,000. BioHealth values the non-controlling interest (NCI) at fair value, which was $2,600,000 at the acquisition date. For the year ended 31 December 20X8, MedTech reported a profit after tax of $1,200,000. No dividends were paid.

What is the carrying amount of the Non-Controlling Interest (NCI) in the consolidated statement of financial position as at 31 December 20X8?

Answer options:

A.

$2,600,000

B.

$2,900,000

C.

$3,500,000

D.

$2,300,000

How to approach this question

Take the NCI at acquisition and add the NCI's share (25%) of the subsidiary's post-acquisition profit.

Full Answer

B.$2,900,000✓ Correct
NCI at acquisition (fair value) = $2,600,000. NCI share of MedTech's post-acquisition profit = 25% × $1,200,000 = $300,000. Carrying amount of NCI at 31 Dec 20X8 = $2,600,000 + $300,000 = $2,900,000.

Common mistakes

Calculating NCI using the proportionate share of net assets method when the question states fair value method is used.

Practice the full ACCA FR — Financial Reporting Practice Exam 6

32 questions · hints · full answers · grading

More questions from this exam